Development of a lyophilised RH1 formulation: A novel DT diaphorase activated alkylating agent

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 4, 2002, Pages 487-492

  Elliott, M A ^a   Ford, S J ^a   Walker, A A ^a   Hargreaves, R H J ^a   Halbert, G W ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2,5 DIAZIRIDINYL 3 HYDROXYMETHYL 6 METHYL 1,4 BENZOQUINONE; ALKYLATING AGENT; AZIRIDINYLBENZOQUINONE DERIVATIVE; BASE; BUFFER; DEXTRAN; EXCIPIENT; MANNITOL; PHOSPHATE; POLYMER; POVIDONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SOLVENT; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CATALYSIS; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DRUG ACTIVATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; ENZYME ACTIVITY; FREEZE DRYING; HIGH TEMPERATURE; PHYSICAL CHEMISTRY; STORAGE TEMPERATURE; TEMPERATURE DEPENDENCE; TUMOR CELL;

ALKYLATING AGENTS; AZIRIDINES; BENZOQUINONES; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DEXTRANS; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; HALF-LIFE; HYDROGEN-ION CONCENTRATION; MANNITOL; MOLECULAR STRUCTURE; NAD(P)H DEHYDROGENASE (QUINONE); POVIDONE; SOLUBILITY; TEMPERATURE;

EID: 0036230011     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021778754     Document Type: Article

References (19)

1. Diazaquinone NSC-182986
2. Impurities in new drug products, step 2
3. Pharmacokinetics of 2, 5-diaziridinyl-3, 6-bis(2-hydroxyethylamino)-1, 4-benzoquinone (Bzq, Nsc-224070) during a phase-I clinical-trial
4. Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins
5. The hypoxic cell: A target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award lecture
6. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
7. Conversion of mitomycin C to 2, 7-diaminomitosene and 10-decarbamoyl 2, 7-diaminomitosene in tumour tissue in vivo
8. A systematic study on the chemical-stability of the novel indoloquinone antitumor agent EO9
9. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
10. Dt-Diaphorase - A historical review
11. Reductive metabolism of diaziquone (Azq) in the S9 fraction of Mcf-7 cells. 2. Enhancement of the alkylating activity of Azq by Nad(P)H-quinone-acceptor oxidoreductase (Dt-Diaphorase)
12. RH1, pre-clinical studies
13. E09 - A novel bioreductive alkylating indoloquinone with preferential solid tumor-activity and lack of bone-marrow toxicity in preclinical models
14. Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent E09
15. The stability of carboquone in aqueous-solution - 2. Kinetics and mechanisms of degradation of 2, 5-bis(1-aziridinyl)-3, 6-dimethyl-1, 4-benzoquinone and 2, 5-bis-(1-aziridinyl)-3, 6-diisopropyl-1, 4-benzoquinone in aqueous-solution
16. 2, 5-Diaziridinyl-3, 6-bis(carboethoxyamino)-1, 4-benzoquinone - 1. Kinetics in aqueous-solutions by high-performance liquid chromatography
17. Development and production of cytotoxic drug formulations for phase I trials
18. A new screening system for NAD(P)H: Quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinyl benzoquinone, RH1, as a NQO1-directed antitumor agent
19. Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones